How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries?–the good, the bad, and the ugly ways
Introduction: There is significant difference in utilization of patented medicines in the EU, as
pharmaceuticals at Western European price levels are usually not cost-effective in Central …
pharmaceuticals at Western European price levels are usually not cost-effective in Central …